Stock Watch: Reclassified Revenues Help Novartis's Fourth Quarter

Last-Minute Revenue Reclassifications Are Probably Not Reproducible

 
• By Andy Smith
  
Andy Smith
ANDY SMITH OFFERS A LIFE SCIENCE INVESTOR'S PERSPECTIVE ON BIOPHARMA BUSINESS
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Earnings

More from Business